Market

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Read More

Related Posts

Alliance Entertainment CEO Jeffrey Walker buys $2.69 billion in stock

Alliance Entertainment CEO Jeffrey Walker buys $2.69 bi...

Factbox-Key economic targets expected to be approved by China's parliament

Factbox-Key economic targets expected to be approved by...

Why Nvidia earnings report is good news for its Big Tech rivals

Why Nvidia earnings report is good news for its Big Tec...

Japan factory output contracts as expected in Jan, retail sales jump

Japan factory output contracts as expected in Jan, reta...

Csg Systems director Ronald Cooper sells $599,580 in stock

Csg Systems director Ronald Cooper sells $599,580 in stock

President Prabowo Inaugurates Pegadaian Gold Bank Service, BRI Group Optimistic in Strengthening the National Economy

President Prabowo Inaugurates Pegadaian Gold Bank Servi...